Brief: Compugen Presents Preliminary Results From Phase 1 Dose Escalation Monotherapy Study Of Com902
12/11/2021 12:39
Nov 12 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN PRESENTS PRELIMINARY RESULTS FROM PHASE 1 DOSE
ESCALATION MONOTHERAPY STUDY OF COM902 A HIGH AFFINITY
ANTI-TIGIT ANTIBODY AT SITC 2021
* COMPUGEN LTD - COM902 IN COMBINATION WITH COM701 COHORT
EXPANSION IN A PD-(L)1 FREE REGIMEN PHASE 1 HAS BEEN INITIATED
* COMPUGEN LTD - COM902, HIGH AFFINITY, IGG4, REDUCED FC
EFFECTOR
FUNCTION, ANTI-TIGIT ANTIBODY WAS WELL TOLERATED WITH A
FAVORABLE SAFETY PROFILE
Source text for Eikon: ID:nPn1x7QyMa
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025